BioNTech Completes Acquisition of Neon Therapeutics

BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of the Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) acquisition through an all-stock transaction. The merger agreement was first announced on January 16, 2020. The new subsidiary based in Cambridge, Massachusetts, will operate under the name of BioNTech US Inc. and serve as BioNTech’s U.S. headquarters. As of May 7, 2020, Neon’s common stock will no longer be available for trading.

Comments are closed.